

04 May 2020

Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")

Results of General Meeting and Total Voting Rights

Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, is pleased to announce that at the General Meeting held earlier today, all resolutions proposed were duly passed on a poll by shareholders. A summary of the voting results is shown below:

	For	Discretion	Against	Withheld	Total Votes Cast	% Voting For*
Resolution 1	107,384,236	-	-	-	107,384,236	100.00
Resolution 2	107,294,236	-	90,000	-	107,384,236	99.92

* This column represents the number of votes that were cast for the resolutions as a percentage of the number of votes cast in total for each resolution either in person or by proxy.

Accordingly, the Company will raise a total of approximately £5.2 million (before expenses) via the Placing through the issue and allotment of 49,400,000 new Ordinary Shares. An application has been made for the 35,637,769 EIS/VCT Placing Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 5 May 2020. A further application has been made for the 13,762,231 General Placing Shares to be admitted to trading on AIM, which is expected to take place at 8.00 a.m. on 6 May 2020.

Following admission of both the EIS/VCT Placing Shares and the General Placing Shares, the Company's issued share capital will comprise 269,396,792 Ordinary Shares, of which none are held in treasury. The above figure of 269,396,792 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 17 April 2020.

Enquiries:

Intelligent Ultrasound Group plc

Stuart Gall, CEO
Helen Jones, CFO

www.intelligentultrasound.com

Tel: +44 (0)29 2075 6534

Cenkos Securities plc

Giles Balleny/Cameron MacRitchie (Nominated Adviser)
Michael Johnson/Julian Morse (Corporate Broking)

Tel: +44 (0)20 7397 8900

Walbrook PR

Anna Dunphy/Paul McManus

Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com

Mob: +44 (0)7876 741 001/Mob: +44 (0)7980 541 893

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.

Based in Cardiff and Oxford in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:

Clinical AI Division

Focuses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.

Simulation Division

Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eye Point of Care and Emergency Medicine training simulator. To date over 800 simulators have been sold to almost 500 medical institutions around the world.

www.intelligentultrasound.com